Germany

BMI View: The importance of maintaining healthy research and development (R&D) pipelines and launching new drugs by innovative drugmakers cannot be stressed enough. The patent cliff... 2011-12-20

BMI View: In the short term, the halt in the delivery of drugs to German medicine wholesalers while Novartis negotiates discounts on drugs (fuelled by low interest rates and wholesalers'... 2011-12-02

BMI Core View: Governments will increasingly impose price controls on pharmaceuticals. Drugmakers have generally charged what the market will bear in developed and emerging markets.... 2011-11-25

The German government remains committed to its fiscal austerity programme, through which Minister of Finance Wolfgang Schauble plans to cut spending by EUR80bn (US$103bn) by 2014. With... 2011-09-29

BMI View: Despite the threat of austerity measures and the government's focus on cost-containment within the pharmaceuticals and healthcare sector, as well as the impact of generic... 2011-09-08

BMI view: Deficits remain a key challenge for the majority of governments across Europe. While many sectors may see only limited downside risks from the situation, the pharmaceutical... 2011-07-25

BMI Core View: Post-marketing surveillance trials will become standard in the pharmaceutical industry. Currently, these phase IV studies are infrequently employed, mainly due to the... 2011-06-10